Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice
- PMID: 15987683
- DOI: 10.1074/jbc.M505249200
Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice
Abstract
Beta-secretase (BACE1) is the rate-limiting protease for the generation of the amyloid beta-peptide (Abeta) in Alzheimer disease. Mice in which the bace1 gene is inactivated are reported to be healthy. However, the presence of a homologous gene encoding BACE2 raises the possibility of compensatory mechanisms. Therefore, we have generated bace1, bace2, and double knockout mice. We report here that BACE1 mice display a complex phenotype. A variable but significant number of BACE1 offspring died in the first weeks after birth. The surviving mice remained smaller than their littermate controls and presented a hyperactive behavior. Electrophysiologically, subtle alterations in the steady-state inactivation of voltage-gated sodium channels in BACE1-deficient neurons were observed. In contrast, bace2 knockout mice displayed an overall healthy phenotype. However, a combined deficiency of BACE2 and BACE1 enhanced the bace1-/- lethality phenotype. At the biochemical level, we have confirmed that BACE1 deficiency results in an almost complete block of Abeta generation in neurons, but not in glia. As glia are 10 times more abundant in brain compared with neurons, our data indicate that BACE2 could indeed contribute to Abeta generation in the brains of Alzheimer disease and, in particular, Down syndrome patients. In conclusion, our data challenge the general idea of BACE1 as a safe drug _target and call for some caution when claiming that no major side effects should be expected from blocking BACE1 activity.
Similar articles
-
Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes.FASEB J. 2005 May;19(7):739-49. doi: 10.1096/fj.04-3426com. FASEB J. 2005. PMID: 15857888
-
The beta-secretase, BACE: a prime drug _target for Alzheimer's disease.J Mol Neurosci. 2001 Oct;17(2):157-70. doi: 10.1385/JMN:17:2:157. J Mol Neurosci. 2001. PMID: 11816789 Review.
-
Beta-secretase cleavage at amino acid residue 34 in the amyloid beta peptide is dependent upon gamma-secretase activity.J Biol Chem. 2003 Jun 6;278(23):21286-94. doi: 10.1074/jbc.M209859200. Epub 2003 Mar 27. J Biol Chem. 2003. PMID: 12665519
-
Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice.Sci Rep. 2016 Feb 25;6:21917. doi: 10.1038/srep21917. Sci Rep. 2016. PMID: 26912421 Free PMC article.
-
BACE1: the beta-secretase enzyme in Alzheimer's disease.J Mol Neurosci. 2004;23(1-2):105-14. doi: 10.1385/JMN:23:1-2:105. J Mol Neurosci. 2004. PMID: 15126696 Review.
Cited by
-
Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer's disease.Sci Transl Med. 2016 May 25;8(340):340ra72. doi: 10.1126/scitranslmed.aaf1059. Sci Transl Med. 2016. PMID: 27225182 Free PMC article.
-
BACE1 as a therapeutic _target in Alzheimer's disease: rationale and current status.Drugs Aging. 2013 Oct;30(10):755-64. doi: 10.1007/s40266-013-0099-3. Drugs Aging. 2013. PMID: 23842796 Review.
-
Critical analysis of the use of β-site amyloid precursor protein-cleaving enzyme 1 inhibitors in the treatment of Alzheimer's disease.Degener Neurol Neuromuscul Dis. 2014 Jan 22;4:1-19. doi: 10.2147/DNND.S41056. eCollection 2014. Degener Neurol Neuromuscul Dis. 2014. PMID: 32669897 Free PMC article. Review.
-
Therapeutic strategies for Alzheimer's disease.Mol Neurobiol. 2008 Apr-Jun;37(2-3):171-86. doi: 10.1007/s12035-008-8031-2. Epub 2008 Jun 26. Mol Neurobiol. 2008. PMID: 18581273 Review.
-
Using the zebrafish model for Alzheimer's disease research.Front Genet. 2014 Jun 30;5:189. doi: 10.3389/fgene.2014.00189. eCollection 2014. Front Genet. 2014. PMID: 25071820 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous